Siglin J C, Barch D H, Stoner G D
Department of Pathology, Medical College of Ohio, Toledo 43699-0008, USA.
Carcinogenesis. 1995 May;16(5):1101-6. doi: 10.1093/carcin/16.5.1101.
The potential inhibitory effects of phenethyl isothiocyanate (PEITC), ellagic acid (EA), sulindac and supplemental dietary calcium (SDC) on N-nitrosomethylbenzylamine (NMBA)-induced esophageal carcinogenesis were evaluated in rats utilizing an abbreviated (5 week) NMBA treatment protocol which allowed administration of the putative inhibitors throughout the experiment (i.e. beginning 2 weeks prior to NMBA treatment) or following completion of NMBA dosing only. PEITC at 500 p.p.m. significantly inhibited tumor incidence and multiplicity when given before and during, but not following, NMBA treatment. Neither sulindac at 125 p.p.m. nor SDC (2% versus 0.5% in control diet) inhibited tumor development when given during or following NMBA treatment. EA, which was administered only following NMBA treatment, significantly reduced the incidence (66.7% versus 100% in NMBA controls), but not the multiplicity, of esophageal tumors at the high-dose (4000 p.p.m.) level. Together these findings indicate that: (i) PEITC selectively inhibits the induction but not the subsequent progression of NMBA-induced esophageal tumors; (ii) EA may repress esophageal tumor development when administered following NMBA treatment; (iii) at the doses administered, neither sulindac nor SDC possess significant inhibitory activity against NMBA-induced esophageal carcinogenesis in the rat.
利用一种简化的(5周)N-亚硝基甲基苄胺(NMBA)处理方案,在大鼠中评估了异硫氰酸苯乙酯(PEITC)、鞣花酸(EA)、舒林酸和补充膳食钙(SDC)对NMBA诱导的食管癌发生的潜在抑制作用。该方案允许在整个实验过程中(即在NMBA处理前2周开始)或仅在NMBA给药完成后给予假定的抑制剂。当在NMBA处理之前和期间给予500 ppm的PEITC时,可显著抑制肿瘤发生率和肿瘤数量,但在NMBA处理之后给予则无此效果。当在NMBA处理期间或之后给予时,125 ppm的舒林酸和SDC(对照饮食中为2%,而不是0.5%)均未抑制肿瘤发展。仅在NMBA处理后给予的EA,在高剂量(4000 ppm)水平时,可显著降低食管肿瘤的发生率(NMBA对照组为100%,EA处理组为66.7%),但不能降低肿瘤数量。这些研究结果共同表明:(i)PEITC选择性抑制NMBA诱导的食管肿瘤起始,但不抑制其后续进展;(ii)在NMBA处理后给予EA可能会抑制食管肿瘤发展;(iii)在所给予的剂量下,舒林酸和SDC对大鼠中NMBA诱导的食管癌发生均不具有显著抑制活性。